Anno XII, nr 7, Aprile 2025
DOI 10.19156/abm.2025.0002
Indice
Prefazione
Trattamento precoce con dose ottimale di ruxolitinib in una paziente con mielofibrosi post-trombocitemia essenziale
Mielofi rosi secondaria a trombocitemia essenziale candidata a trapianto allogenico
Quando il trattamento precoce è la chiave di volta
Trattamento precoce con ruxolitinib nel paziente affetto da mielofibrosi
HPS srl
Milano: Piazza Duca d’Aosta, 12 – 20124 – Tel +39 02 2772 991 (Sede legale)
Roma: Viale dell’Arte, 25 – 00144
PEC hps.srl@legalmail.it | P.IVA 07106000966 | REA MI – 1935962 | Capitale Sociale: €20.000 i.v.
| Cookie | Durata | Descrizione |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
